Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)

A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)

Also Known As:

Networked: 1065 relevant articles (92 outcomes, 107 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Youdim, Moussa B H: 14 articles (11/2018 - 12/2002)
2.	Petzer, Jacobus P: 13 articles (08/2022 - 01/2015)
3.	Petzer, Anél: 12 articles (11/2019 - 03/2015)
4.	Baker, Glen B: 9 articles (07/2022 - 01/2002)
5.	Thase, Michael E: 7 articles (07/2022 - 01/2003)
6.	Marco-Contelles, José: 6 articles (11/2020 - 12/2011)
7.	Bar-Am, Orit: 6 articles (01/2017 - 10/2005)
8.	Dhiman, Priyanka: 5 articles (12/2019 - 01/2018)
9.	Khatkar, Anurag: 5 articles (12/2019 - 01/2018)
10.	Malik, Neelam: 5 articles (12/2019 - 01/2018)

Related Diseases

1.	Panic Disorder (Panic Attack) 11/01/1990 - "Tricyclics and MAO inhibitors are effective in panic disorders. " 01/01/1989 - "Monoamine oxidase inhibitors are effective in the treatment of panic attacks. " 09/01/1992 - "Monoamine oxidase inhibitors may be particularly helpful in patients with panic disorder who exhibit social avoidance. " 03/01/1995 - "It is generally thought that atypical depression would respond better to monoamine oxidase inhibitors (MAOI), but it would seem that it is mainly major depression associated with panic disorder that could predict this kind of response to treatment. " 01/01/1992 - "The monoamine oxidase inhibitors have also proved very useful in the treatment of panic disorder and social phobia, but probably should be used only by physicians with experience with this type of medication."
2.	Social Phobia 06/01/1994 - "Previous studies have shown selective and nonselective monoamine oxidase inhibitors (MAOIs) to be effective in the treatment of social phobia. " 12/01/2002 - "The efficacy of irreversible and reversible monoamine oxidase inhibitors (MAOIs) in the treatment of social phobia (SP) is well established. " 01/01/1999 - "Efficacy in social phobia was reported with the MAOIs and this led to the investigation of reversible inhibitors of monoamine oxidase-A (RIMA) which offer a safer alternative. " 04/01/1992 - "Overall, the findings support the responsivity of social phobia to monoamine oxidase inhibitors." 01/01/1992 - "The monoamine oxidase inhibitors have also proved very useful in the treatment of panic disorder and social phobia, but probably should be used only by physicians with experience with this type of medication."
3.	Agoraphobia 01/01/1988 - "Monoamine oxidase inhibitors (MAOI's) have been shown to be significantly superior to placebo in the treatment of some anxiety disorders, particularly agoraphobia and mixed anxiety--depressive states. " 01/01/1983 - "discrete episodes of severe acute anxiety with clear "onset" and "offset" are frequently associated with agoraphobia and respond to tricyclic and MAO-inhibitor antidepressants. " 12/01/1982 - "Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of agoraphobia." 03/01/1985 - "This article reviews the evidence on the efficacy of monoamine oxidase inhibitors (MAOIs) and of alprazolam in the treatment of panic disorder and agoraphobia. " 12/01/1982 - "The efficacy of tricyclic antidepressants and monoamine oxidase inhibitors for the treatment of agoraphobia and other panic disorders is reviewed with an emphasis on controlled prospective studies. "
4.	Parkinson Disease (Parkinson's Disease) 11/01/2019 - "This study proposes that high potency MAO inhibitors such as those investigated here, may act as lead compounds for the development of treatments for neurodegenerative and neuropsychiatric disorders such as Parkinson's disease and depression." 11/06/2023 - "Safety comparisons among monoamine oxidase inhibitors against Parkinson's disease using FDA adverse event reporting system." 01/01/2023 - "MAO inhibitors (MAOIs) are frequently utilized to treat disorders such as major depression or Parkinson's disease (PD), though their effects on brain mitochondrial bioenergetics are unclear. " 12/01/2022 - "MAO inhibitors have been used clinically to treat depression, anxiety, and Parkinson's disease. " 01/01/2018 - "It may be concluded that active MAO inhibitors, such as 10 represent suitable leads for the development of drugs for neurodegenerative and neuropsychiatric disorders such as Parkinson's disease and depression. "
5.	Treatment-Resistant Depressive Disorder 01/01/2020 - "Reactions on 'The effectiveness of monoamine oxidase inhibitors in treatment-resistant depressive disorders in clinical practice; a retrospective open-label study'." 01/01/2020 - "[Reactions on 'The effectiveness of monoamine oxidase inhibitors in treatment-resistant depressive disorders in clinical practice; a retrospective open-label study']." 01/01/2020 - "Three patients (18%) quitted because of side-effects.<br/> CONCLUSION: The results of this and similar studies are modest and ask for critical thinking and critical prescribing of mao-inhibitors, because of the possibly limited effectiveness in treatment-resistant depressions." 01/01/2020 - "[The effectiveness of monoamine oxidase inhibitors in treatment-resistant depressive disorders in clinical practice; a retrospective open-label study]." 12/21/2015 - "[The use of the monoamine oxidase inhibitor isocarboxazide in treatment-resistant depression]."

Related Drugs and Biologics

1.	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)
2.	Antidepressive Agents (Antidepressants)
3.	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)
4.	Benzodiazepines
5.	Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)
6.	Monoamine Oxidase (MAO)
7.	Phenelzine (Nardil)
8.	Moclobemide (Arima)
9.	Imipramine (Janimine)
10.	Alprazolam (Xanax)

Related Therapies and Procedures

1.	Therapeutics
2.	Blood Pressure Monitors
3.	Diet Therapy (Therapy, Diet)
4.	Aftercare (After-Treatment)
5.	Drug Therapy (Chemotherapy)